SNMMI annual meeting featured a clinical diagnosis and therapy session and a presentation by Dr. Kambiz Rahbar discussing the utility of the PROSTest to predict response to 177 Lu-PSMA therapy in ...

SNMMI annual meeting featured a clinical diagnosis and therapy session and a presentation by Dr. Kambiz Rahbar discussing the clinical value of the PROSTest to detect biochemical recurrence in ...

At the 2025 UCSF-UCLA PSMA Conference, Matthias Eiber compares PSMA-617 and PSMA-I&T radiopharmaceuticals. He notes both agents share binding motifs but differ in chelator properties and linker ...

AUA 2025 thermal safety of high-powered lasers during endoscopic stone surgery, renal calyceal, parenchymal temperatures, laser lithotripsy, 60W Super-Pulse Thulium Fiber Laser (TFL), 120W ...

Zachary Klaassen speaks with Adrien Holzgreve about the FLEX-MRT trial, which aims to personalize lutetium-177 PSMA radioligand therapy delivery. Currently, Pluvicto™ follows fixed dosing from the ...

Zachary Klaassen hosts Alessandro Viti to discuss early oncological outcomes in very high-risk prostate cancer patients using PSMA-PET imaging. Dr. Viti addresses the research question of how surgery ...

Bladder Cancer - Read the latest Bladder Cancer research including Full-Text Abstracts as well as "Beyond the Abstract" articles, written by the researchers exclusively for UroToday.

UroToday's exclusive Video Lecture content covering Advanced Prostate Cancer.

Clear explanation of what a "Foley" or indwelling catheter is, the 2 types of insertions, their use cases, and the risk of CAUTI if catheterization isn't properly managed.

Prostatitis - Read the latest Prostatitis research including Full-Text Abstracts as well as "Beyond the Abstract" articles, written by the researchers exclusively for UroToday.

Bladder Research - Read the latest Bladder Research research including Full-Text Abstracts as well as "Beyond the Abstract" articles, written by the researchers exclusively for UroToday.

CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC CG Oncology, Inc.